BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33. [PMID: 16120759 DOI: 10.1136/gut.2005.075937] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
2 Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19:61-68. [PMID: 23378357 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
3 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 El Mansouri L, Couchouron T, Le Roux G, Dugast C, Burtin F, Albert JD, Perdriger A, Hassouni NH, Chalès G. Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists. Joint Bone Spine 2009;76:421-3. [PMID: 19457692 DOI: 10.1016/j.jbspin.2008.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
6 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
7 Krane MK, Allaix ME, Zoccali M, Umanskiy K, Rubin MA, Villa A, Hurst RD, Fichera A. Preoperative Infliximab Therapy Does Not Increase Morbidity and Mortality After Laparoscopic Resection for Inflammatory Bowel Disease. Diseases of the Colon & Rectum 2013;56:449-57. [DOI: 10.1097/dcr.0b013e3182759029] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
8 Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn’s disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 2007;25:787-796. [PMID: 17373917 DOI: 10.1111/j.1365-2036.2007.03253.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
9 De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, Van Rheenen PF, Schweizer JJ, Hoekstra JH, Norbruis OF, Tjon A Ten WE, Vreugdenhil AC, Deckers-Kocken JM, Gijsbers CF, Escher JC, De Ridder L. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther. 2011;33:243-250. [PMID: 21083595 DOI: 10.1111/j.1365-2036.2010.04507.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
10 Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P. Risk of Malignant Cancers in Inflammatory Bowel Disease. J Crohns Colitis 2019;13:1302-10. [PMID: 30874294 DOI: 10.1093/ecco-jcc/jjz058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
11 Biancone L, Armuzzi A, Scribano ML, D’inca R, Castiglione F, Papi C, Angelucci E, Daperno M, Mocciaro F, Riegler G, Fries W, Meucci G, Alvisi P, Spina L, Ardizzone S, Petruzziello C, Ruffa A, Kohn A, Vecchi M, Guidi L, Di Mitri R, Renna S, Emma C, Rogai F, Rossi A, Orlando A, Pallone F; on behalf of the Italian Group for the study of Inflammatory Bowel Disease. Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. ECCOJC 2016;10:913-24. [DOI: 10.1093/ecco-jcc/jjw048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
12 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
13 Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, Ferrante M. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Eur J Gastroenterol Hepatol 2017;29:84-90. [PMID: 27603297 DOI: 10.1097/MEG.0000000000000735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
14 Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY. Mucinous carcinoma in Crohn’s disease originating in a fistulous tract. World J Gastrointest Oncol 2010; 2(7): 307-310 [PMID: 21160662 DOI: 10.4251/wjgo.v2.i7.307] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Mohammad F, Vivekanandarajah A, Haddad H, Shutty CM, Hurford MT, Dai Q. Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature. BMJ Case Rep 2014;2014:bcr2013203318. [PMID: 24842356 DOI: 10.1136/bcr-2013-203318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
17 Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31:553-60. [PMID: 20002026 DOI: 10.1111/j.1365-2036.2009.04206.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
18 Alkhayyat M, Abureesh M, Gill A, Khoudari G, Abou Saleh M, Mansoor E, Regueiro M. Lower Rates of Colorectal Cancer in Patients With Inflammatory Bowel Disease Using Anti-TNF Therapy. Inflamm Bowel Dis 2021;27:1052-60. [PMID: 33051651 DOI: 10.1093/ibd/izaa252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Stuby U, Biesenbach G, Pieringer H. Administration of infliximab in general practitioners’ offices is safe. Clin Rheumatol 2007;26:1863-6. [DOI: 10.1007/s10067-007-0590-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Elandt K, Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011;13:223. [PMID: 21722342 DOI: 10.1186/ar3352] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
21 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 13.7] [Reference Citation Analysis]
22 Ferraro S, Leonardi L, Convertino I, Blandizzi C, Tuccori M. Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. Front Pharmacol 2019;10:247. [PMID: 30941038 DOI: 10.3389/fphar.2019.00247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674-698. [PMID: 25545375 DOI: 10.1097/mib.0000000000000243] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
24 Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI, Berinstein JA, Allin KH, Jess T. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol 2020;5:276-84. [PMID: 31836320 DOI: 10.1016/S2468-1253(19)30362-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
25 Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, Helzlsouer KJ, Jabs DA, Kaçmaz RO, Levy-Clarke GA, Liesegang TL, Newcomb CW, Nussenblatt RB, Pujari SS, Rosenbaum JT, Suhler EB, Thorne JE. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480. [PMID: 19578087 DOI: 10.1136/bmj.b2480] [Cited by in Crossref: 132] [Cited by in F6Publishing: 101] [Article Influence: 10.2] [Reference Citation Analysis]
26 Vuitton L, Jacquin E, Parmentier AL, Crochet E, Fein F, Dupont-Gossart AC, Plastaras L, Bretagne CH, Mauny F, Koch S, Prétet JL, Mougin C, Valmary-Degano S. High Prevalence of Anal Canal High-Risk Human Papillomavirus Infection in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:1768-1776.e5. [PMID: 29551740 DOI: 10.1016/j.cgh.2018.03.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Mager LF, Wasmer MH, Rau TT, Krebs P. Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol. 2016;6:96. [PMID: 27148488 DOI: 10.3389/fonc.2016.00096] [Cited by in Crossref: 102] [Cited by in F6Publishing: 102] [Article Influence: 17.0] [Reference Citation Analysis]
28 Domènech E, Zabana Y, Mañosa M, Garcia-planella E, Cabré E, Gassull MÀ. Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen. Journal of Clinical Gastroenterology 2010;44:34-7. [DOI: 10.1097/mcg.0b013e3181962dfa] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
29 Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4:511-522. [PMID: 21122554 DOI: 10.1016/j.crohns.2010.05.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
30 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
31 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
32 Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602; quiz 1593, 1603. [PMID: 21844919 DOI: 10.1038/ajg.2011.211] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
33 Dulai PS, Sandborn WJ, Gupta S. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016;9:887-894. [PMID: 27679553 DOI: 10.1158/1940-6207.capr-16-0124] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
34 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
35 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881. [PMID: 19558997 DOI: 10.1016/j.cgh.2009.01.004] [Cited by in Crossref: 345] [Cited by in F6Publishing: 314] [Article Influence: 26.5] [Reference Citation Analysis]
36 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
37 Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma. 2007;48:1410-1413. [PMID: 17613771 DOI: 10.1080/10428190701345433] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
38 Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R. Infliximab and the risk of latent viruses reactivation in active Crohn’s disease. Inflamm Bowel Dis. 2007;13:896-902. [PMID: 17345605 DOI: 10.1002/ibd.20131] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
39 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
40 Friedman S. Cancer in Crohn’s disease. Gastroenterol Clin North Am. 2006;35:621-639. [PMID: 16952744 DOI: 10.1016/j.gtc.2006.07.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
41 Rojas-Feria M, Eslam M, Castro-Fernández M, Guerrero P, Larraona-Moreno JL, Romero-Gómez M. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. J Crohns Colitis 2011;5:608-11. [PMID: 22115382 DOI: 10.1016/j.crohns.2011.04.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
42 Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol 2015;5:156-63. [PMID: 29018691 DOI: 10.1016/j.tjo.2015.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
43 Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030. [PMID: 17480018 DOI: 10.1002/ibd.20169] [Cited by in Crossref: 169] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
44 Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012;6:578-587. [PMID: 22398047 DOI: 10.1016/j.crohns.2011.11.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
45 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9:945-965. [PMID: 26294789 DOI: 10.1093/ecco-jcc/jjv141] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 27.0] [Reference Citation Analysis]
46 Scaringi S, Di Martino C, Zambonin D, Fazi M, Canonico G, Leo F, Ficari F, Tonelli F. Colorectal cancer and Crohn's colitis: clinical implications from 313 surgical patients. World J Surg 2013;37:902-10. [PMID: 23381673 DOI: 10.1007/s00268-013-1922-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
47 López San Román A, Van Domselaar M, Rivero M, Redondo C, Arribas R, Rey A. Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab. J Crohns Colitis 2008;2:93-6. [PMID: 21172197 DOI: 10.1016/j.crohns.2007.10.005] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
48 O'Donnell S, Murphy S, Anwar MM, O'Sullivan M, Breslin N, O'Connor HJ, Ryan BM, O'Morain CA. Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol 2011;23:603-6. [PMID: 21602689 DOI: 10.1097/MEG.0b013e3283479125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology 2008;58:94-105. [DOI: 10.1016/j.jaad.2007.08.030] [Cited by in Crossref: 85] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
50 Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119-130. [PMID: 20412066 DOI: 10.1111/j.1365-2036.2010.04330.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
51 Bremner A, Beattie R. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opinion on Pharmacotherapy 2007;8:2553-68. [DOI: 10.1517/14656566.8.15.2553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
52 Teitelbaum JE, Saeed S, Triantafyllopoulou M, Daum F. Infliximab in Pediatric Crohn Disease Patients With Enterovesicular Fistulas. Journal of Pediatric Gastroenterology & Nutrition 2007;44:279-82. [DOI: 10.1097/01.mpg.0000237933.38223.da] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
53 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
54 Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Helzlsouer KJ. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008;146:802-12.e1. [PMID: 18579112 DOI: 10.1016/j.ajo.2008.04.035] [Cited by in Crossref: 95] [Cited by in F6Publishing: 75] [Article Influence: 6.8] [Reference Citation Analysis]
55 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
56 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
57 Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol 2008; 14(25): 3937-3947 [PMID: 18609676 DOI: 10.3748/wjg.14.3937] [Cited by in CrossRef: 231] [Cited by in F6Publishing: 213] [Article Influence: 16.5] [Reference Citation Analysis]
58 Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
59 Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer 2008;7:260-6. [PMID: 18650194 DOI: 10.3816/CCC.2008.n.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
60 Subramaniam K, Tucker K, Craft P, Pavli P. Should patients be screened for hereditary cancer syndromes before starting anti-TNF-α therapy? Inflamm Bowel Dis 2011;17:E151-2. [PMID: 21987302 DOI: 10.1002/ibd.21883] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm Bowel Dis 2013;19:644-9. [PMID: 23314243 DOI: 10.1097/MIB.0b013e318280ebbd] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
62 Sorrentino D, Terrosu G, Avellini C. Infliximab in Crohn's disease: a look at the (not so distant) future. Dig Liver Dis 2008;40 Suppl 2:S229-35. [PMID: 18598994 DOI: 10.1016/S1590-8658(08)60531-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Yang C, Huang J, Huang X, Huang S, Cheng J, Liao W, Chen X, Wang X, Dai S. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:1042-52. [PMID: 29762681 DOI: 10.1093/ecco-jcc/jjy065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
64 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
65 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
66 Angelucci E, Cesarini M, Vernia P. Nonmelanoma skin cancers in four IBD patients on treatment with immunosuppressive agents: . Inflammatory Bowel Diseases 2011;17:1827-9. [DOI: 10.1002/ibd.21609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23:395-399. [PMID: 17545775 DOI: 10.1097/mog.0b013e32815b601b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
68 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
69 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
70 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
71 Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'Incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflamm Bowel Dis 2020;26:450-9. [PMID: 31498388 DOI: 10.1093/ibd/izz155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
72 Connell W, Andrews JM, Brown S, Sparrow M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia: Safety of anti TNF treatment in IBD. Internal Medicine Journal 2010;40:139-49. [DOI: 10.1111/j.1445-5994.2009.02122.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
73 Kuehn F, Mullins CS, Krohn M, Harnack C, Ramer R, Krämer OH, Klar E, Huehns M, Linnebacher M. Establishment and characterization of HROC69 - a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft. Sci Rep 2016;6:24671. [PMID: 27087592 DOI: 10.1038/srep24671] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
74 Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
75 van de Ven SEM, Derikx LAAP, Nagtegaal ID, van Herpen CM, Takes RP, Melchers WJG, Pierik M, van den Heuvel T, Verhoeven RHA, Hoentjen F, Nissen LHC. Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors. Inflamm Bowel Dis 2020;26:1060-7. [PMID: 31559415 DOI: 10.1093/ibd/izz210] [Reference Citation Analysis]
76 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
77 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
78 Mala A, Foteinogiannopoulou K, Koutroubakis IE. Solid extraintestinal malignancies in patients with inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(12): 1956-1980 [DOI: 10.4251/wjgo.v13.i12.1956] [Reference Citation Analysis]
79 . A cautionary tale of biologic therapy. Internal Medicine Journal 2009;39:e2-4. [DOI: 10.1111/j.1445-5994.2009.02088.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
81 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
82 Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653. [PMID: 18550004 DOI: 10.1016/j.cgh.2008.03.014] [Cited by in Crossref: 397] [Cited by in F6Publishing: 367] [Article Influence: 28.4] [Reference Citation Analysis]